文献速递免疫规划传染病防控与疫情报告

2024年春季(XBB.1.5)与秋季(JN.1)COVID-19疫苗接种对英格兰住院的保护效果

Effectiveness of spring 2024 (XBB.1.5) and autumn 2024 (JN.1) COVID-19 vaccination against hospitalisation in England.
PubMed 文献 · Vaccine · 2025-10-23

在英格兰,采用检测阴性病例对照设计评估2024年春季XBB.1.5疫苗和秋季JN.1疫苗对COVID-19住院的保护效果。XBB.1.5疫苗在接种后2-4周保护效果峰值45%(95%CI:37-52%),至25-29周降至6%(95%CI:-11-21%);JN.1疫苗在10-14周峰值43%(95%CI:34-51%),20周时降至34%(95%CI:22-44%)。两种疫苗均提供中等保护,秋季不同厂商间无显著差异。

要点

  • 春季XBB.1.5疫苗对住院保护峰值45%,25-29周降至6%。
  • 秋季JN.1疫苗保护10-14周达43%,20周时为34%。
  • 秋季不同厂商疫苗间保护效果无显著差异。

核心结论

  • 2024年春季XBB.1.5疫苗和秋季JN.1疫苗在英格兰对符合条件老年人的COVID-19住院提供了至少20周的中等保护。
  • 与早期接种活动相比,较低的保护效果可能反映人群免疫水平较高和谱系循环异质性。

研究设计与样本

  • 采用检测阴性病例对照研究设计,估计2024年春季和秋季COVID-19疫苗规划中XBB.1.5和JN.1疫苗对COVID-19住院的保护效果。
  • 使用逻辑回归计算符合条件且因COVID-19住院个体的疫苗有效性(VE),暴露变量为相应接种活动中的接种状态,结局变量为SARS-CoV-2检测结果,并调整协变量。
  • 按制造商进行单独分析。

主要发现

  • 2024年春季接种的XBB.1.5疫苗提供中等保护,2-4周内峰值45%(95%CI:37-52%),至25-29周降至6%(95%CI:-11-21%)。
  • 2024年秋季JN.1疫苗保护效果在10-14周峰值43%(95%CI:34-51%),20周时降至34%(95%CI:22-44%);需进一步监测以评估JN.1疫苗的长期保护。
  • 秋季接种活动中,不同制造商疫苗间保护效果无显著差异。

局限性

  • 需进一步监测以评估JN.1疫苗的长期保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In England, Omicron XBB.1.5 vaccines were offered through the spring 2024 COVID-19 vaccination campaign, targeting adults aged 75 and over and immunosuppressed individuals. The autumn 2024 campaign included adults 65 and over and clinical risk groups, offering Omicron JN.1 vaccines. This study evaluates vaccine effectiveness (VE) and waning protection of vaccines offered in the 2024 campaigns against COVID-19 hospitalisation. METHODS: A test-negative case-control study design was used to estimate effectiveness of XBB.1.5 and JN.1 vaccines provided in the spring and autumn 2024 COVID-19 vaccine programmes respectively against COVID-19 hospitalisation. Logistic regression was used to calculate VE among eligible individuals hospitalised with COVID-19, where the exposure variable was vaccination status in the respective campaign and the outcome variable was SARS-CoV-2 test result, with adjustment for covariates. Separate analyses were conducted by manufacturer. RESULTS: XBB.1.5 vaccines administered in spring 2024 conferred moderate protection, peaking at 45 % (95 % CI: 37-52 %) within 2-4 weeks, declining to 6 % (95 % CI: -11-21 %) by weeks 25-29. VE of Autumn 2024 JN.1 vaccines peaked at 43 % (95 % CI: 34-51 %) effectiveness at 10-14 weeks, falling to 34 % (95 % CI: 22-44 %) by 20 weeks; further monitoring is needed to evaluate long-term protection of the JN.1 vaccine. No significant differences in effectiveness were found between manufacturers in the autumn campaign. CONCLUSIONS: The XBB.1.5 and JN.1 vaccines distributed during the spring and autumn 2024 COVID-19 vaccine campaign in England provided moderate protection against hospitalisation with COVID-19 among older adults eligible for the vaccines for at least 20 weeks after vaccination. The lower VE compared to earlier campaigns may reflect greater population-level immunity and heterogeneous lineage circulation during this period.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Abdul Aziz N, Kirsebom FCM, Allen A, et al. Effectiveness of spring 2024 (XBB.1.5) and autumn 2024 (JN.1) COVID-19 vaccination against hospitalisation in England. Vaccine. 2025. PMID: 41135289. doi:10.1016/j.vaccine.2025.127870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。